JAMA network open

Estimated Number of US Adults with Metabolic-Related Fatty Liver Disease from 2020 to 2050

Updated

Abstract

The prevalence of metabolic dysfunction-associated steatotic liver disease (MASLD) is projected to rise from 33.7% in 2020 to 41.4% by 2050, affecting an estimated 121.9 million people in the US.

  • Cases of metabolic dysfunction-associated steatohepatitis (MASH) are expected to increase from 14.9 million (5.8% of US adults) in 2020 to 23.2 million (7.9%) by 2050.
  • The number of individuals with clinically significant fibrosis (F≥F2) is projected to grow from 6.7 million to 11.7 million during the same period.
  • By 2046 to 2050, MASLD may lead to 22,440 new cases of hepatocellular carcinoma (HCC) and 6,720 new cases of liver transplant (LT) annually, compared to 11,483 new HCC cases and 1,717 new LT cases from 2020 to 2025.
  • Liver-related mortality could increase from 30,500 deaths (1.0% of all-cause deaths) in 2020 to 95,300 deaths (2.4%) by 2050.

Simplified

Full Text

We can’t show the full text here under this license.

Funding

Competing interests

Conflict of Interest Disclosures: Dr Dasarathy reported receiving grants from Cleveland Clinic during the conduct of the study. Dr Alkhouri reported receiving grants from 89bio, Akero Therapeutics, Arbutus Biopharma, AstraZeneca, Better Therapeutics, Boehringer Ingelheim, Bristol Myers Squibb, Corcept Therapeutics, CymaBay Therapeutics, DSM, Galectin Therapeutics, Genentech, Genfit, Gilead Sciences, Healio, Hepagene Therapeutics, Intercept Pharmaceuticals, Inventiva Pharma, Ionis Pharmaceuticals, Ipsen, Madrigal Pharmaceuticals, Merck, NGM Biopharmaceuticals, Noom, NorthSea Therapeutics, Novo Nordisk, Perspectum, Pfizer, Poxel, Viking Therapeutics, and Zydus Pharmaceuticals during the conduct of the study; personal fees from 89bio, Boehringer Ingelheim, Echosens, Fibronostics, Gilead Sciences, Intercept Pharmaceuticals, Ipsen, Madrigal Pharmaceuticals, NorthSea Therapeutics, Novo Nordisk, and Perspectum Consulting outside the submitted work. Dr Herman reported receiving grants from the Agency for Healthcare Research and Quality (AHRQ) during the conduct of the study. Dr Taksler reported receiving grants from National Institute on Aging during the conduct of the study. Dr Deshpande reported receiving personal fees from Merck outside the submitted work. No other disclosures were reported.
PubMed

What Lands in Your Inbox Each Week:

  • 📚7 fresh studies
  • 📝plain-language summaries
  • direct links to original studies
  • 🏅top journal indicators
  • 📅weekly delivery
  • 🧘‍♂️always free